AbbVie Inc. (ABBV) Stock Analysis
Score BCompounder · Grade C · Bearish
$214.93
$236.77
+10.2%
10/10
C
Compounder
Investment Thesis
Price is above modeled value range. Quality supports holding but not attractive for new positions.
Appears undervalued but quality concerns keep the score lower.
For New Investors
Price above modeled value range
For Current Holders
Quantitative score: neutral
Buy if
- Price drops 15-20% (improves asymmetry)
- Bull scenario catalysts materialize
- Market-wide correction creates opportunity
Sell if
- Bear scenario triggers occur
- Quality metrics deteriorate (ROIC declining)
- Better alternatives emerge
Valuation
Fair Value estimate: $236.77 (+10.2%). Slightly undervalued.
PEG-Based EPS
$279.41
FCF DCF Model
$279.41
EV/EBITDA
$172.80
Blended Fair Value
$236.77
Confidence
High
Methods
PEG-Based EPS, FCF 2-Stage DCF, EV/EBITDA
Quality Analysis
71/120 points
Investable (Early-Profit)
Quality Flags
- Early-Profit screen: P/E > 100 + Gross Margin > 50% — adapted metrics used
- Decelerating growth for high-PE: 2%
- Revenue growth inconsistent
- FCF declining despite revenue growth
Market Sentiment
Wall Street Consensus
$260.00
+21.0% Upside
29 analysts
Range: $223.00 — $298.00
Rating: Buy
Our model is slightly more cautious than Wall Street.
Trend & Technical
Price ($214.93) is 0.5% below SMA 200 ($216.00). Bearish trend. Caution on entry.
Tech Score 63/100 — Neutral technical picture. Mixed signals across indicators.
Risk & Reward
Asymmetry Ratio
6.14:1
Expected Return
+24.4%
Bull Upside
+61.4%
Bear Downside
-10.0%
Excellent asymmetry: 6.14:1 ratio. Upside significantly outweighs downside.
Verdict: Very Favorable
Scenario Analysis
Bear
Base
Bull
Buy Zone & Action Plan
See exact entry zones, stop-loss levels, and a personalized action plan.
AI Executive Summary
Get a detailed AI-written breakdown of the investment thesis, risks, and catalysts.
Technical Analysis
RSI, MACD, moving averages, trend signals, and momentum indicators.
Ask AI about this stock
Chat with our AI analyst to ask questions about valuation, risks, or comparisons.
Frequently Asked Questions
What is the fair value of ABBV?
Based on our multi-method conviction analysis, the estimated fair value of AbbVie Inc. (ABBV) is $236.77. This is calculated by blending PEG-Based EPS, FCF 2-Stage DCF, EV/EBITDA and applying a quality premium of 0% based on the company's fundamentals. The confidence level of this estimate is high.
Is ABBV a buy, sell, or hold?
ABBV currently has a HOLD rating with a conviction score of 10/10. Price is above modeled value range. Quality supports holding but not attractive for new positions. Price above modeled value range.
Is ABBV a high-quality stock?
AbbVie Inc. has a quality grade of C (71/120 points), rated as Investable (Early-Profit). Key metrics include ROE of —%, ROIC-WACC spread of —%, and D/E ratio of 0.5x.
What type of stock is ABBV?
ABBV is classified as a "compounder" in our framework. High P/E: 105.9x, High dividend: 3.1%, Mature growth: 1.6%, Large cap: $379.7B, Dividend paying: 3.1%
What do Wall Street analysts say about ABBV?
29 Wall Street analysts have a consensus price target of $260.00 for ABBV, representing +21.0% upside. Targets range from $223.00 to $298.00. The consensus recommendation is "Buy". Our model is slightly more cautious than Wall Street.
What are the risks of investing in ABBV?
The risk/reward asymmetry ratio for ABBV is 6.14:1, rated as Very Favorable. Excellent asymmetry: 6.14:1 ratio. Upside significantly outweighs downside. The expected return is +24.4%, with bull case upside of +61.4% and bear case downside of -10.0%.
What is the current trend for ABBV?
ABBV is in a bearish trend. Price ($214.93) is 0.5% below SMA 200 ($216.00). Bearish trend. Caution on entry. The technical score is 63/100.
Related Stock Analyses
Best Stocks to Buy
Compare Stocks
Get the complete analysis
Scenario targets, buy zones, action plan, executive summary, technical analysis, and AI chat. All free.
Last updated: May 19, 2026 · Framework version 3.7
This analysis is for informational purposes only and should not be considered financial advice. Always do your own research before making investment decisions.